Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic

Current Opinion in Cardiology

Volumn 30, Issue 4, 2015, Pages 361-365

  Vongpatanasin, Wanpen ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chlorthalidone; Hydrochlorothiazide; Hypertension; Thiazide diuretics

Indexed keywords

HYDROCHLOROTHIAZIDE; THIAZIDE DIURETIC AGENT; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG USE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY;

BLOOD PRESSURE; DIURETICS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION;

EID: 84942603045     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000178     Document Type: Review

References (38)

1. Kurtz TW. Chlorthalidone: don't call it 'thiazide-like' anymore. Hypertension 2010; 56:335-337.
2. Beaumont K, Vaughn DA, Fanestil DD. Thiazide diuretic drug receptors in rat kidney: identification with [3H]metolazone. Proc Natl Acad Sci USA 1988; 85:2311-2314.
3. Beermann B, Hellstrom K, Lindstrom B, Rosen A. Binding-site interaction of chlorthalidone and acetazolamide, two drugs transported by red blood cells. Clin Pharmacol Ther 1975; 17:424-432.
4. Johnston MM, Li H, Mufson D. Chlorthalidone analysis using carbonic anhydrase inhibition. J Pharm Sci 1977; 66:1735-1738.
5. Dieterle W, Wagner J, Faigle JW. Binding of chlorthalidone (hygrotonr) to blood components in man. Eur J Clin Pharmacol 1976; 10:37-42.
6. Beermann B, Groschinsky-Grind M, Lindstrom B, Wikland B. Pharmacokinetics of bendroflumenthiazide in hypertensive patients. Eur J Clin Pharmacol 1978; 13:119-124.
7. Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based metaanalysis of hydrochlorothiazide pharmacokinetics. Biopharm Drug Dispos 2013; 34:527-539.
8. Schiavi P, Jochemsen R, Guez D. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam Clin Pharmacol 2000; 14:139-146.
9. Messerli FH, Makani H, Benjo A, et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a metaanalysis of randomized trials. J Am Coll Cardiol 2011; 57:590-600.
10. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of doseresponse relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59:1104-1109.
11. (UK) NCGC. Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet]. 2011. Available from: http://www. ncbi. nlm. nih. gov/pubmed/22855971. [Accessed 9 February 2015]
12. van Blijderveen JC, Straus SM, Rodenburg EM, et al. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med 2014; 127:763-771.
13. Matthews KA, Brenner MJ, Brenner AC. Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. Clin Ther 2013; 35:1423-1430.
14. Wilson L, Nair KV, Saseen JJ. Comparison of new-onset gout in adults prescribed chlorthalidone vs hydrochlorothiazide for hypertension. J Clin Hypertens 2014; 16:864-868.
15. Cooper-DeHoff RM, Wen S, Beitelshees AL, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010; 55:61-68.
16. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008; 117:2706-2715.
17. Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab 2009; 94:1361-1366.
18. Raheja P, Price A, Wang Z, et al. Spironolactone prevents chlorthalidoneinduced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 2012; 60:319-325.
19. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diureticbased therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95:29-35.
20. Barzilay JI, Davis BR, Pressel SL, et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes 2012; 5:153-162.
21. Almgren T, Wilhelmsen L, Samuelsson O, et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007; 25:1311-1317.
22. Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57:689-694.
23. Ernst ME, Neaton JD, Grimm RH Jr, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension 2011; 58:1001-1007.
24. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
25. Jamerson KA, Bakris GL, Weber MA. 24-h ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med 2010; 363:98.
26. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293:1595-1608.
27. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59:1110-1117.
28. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension 2010; 56:463-470.
29. Dell'Omo G, Penno G, Del Prato S, Pedrinelli R. Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. J Cardiovasc Pharmacol Ther 2005; 10:265-272.
30. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282:539-546.
31. Fan HQ, Li Y, Thijs L, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 2010; 28:2036-2045.
32. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47:352-358.
33. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125:1229. e1-1229. e10.
34. Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013; 381:537-545.
35. Reisin E, Graves JW, Yamal JM, et al. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. J Hypertens 2014; 32:1503-1513.
36. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
37. Ernst ME, Lund BC. Renewed interest in chlorthalidone: evidence from the Veterans Health Administration. J Clin Hypertens 2010; 12:927-934.
38. Fontil V, Pletcher MJ, Khanna R, et al. Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010. J Gen Intern Med 2014; 29:468-476.